Categories: News

OpGen to Provide Business Update and Financial Results for the Third Quarter 2021 on November 11th at 4:30 p.m. Eastern Time

ROCKVILLE, Md., Oct. 28, 2021 (GLOBE NEWSWIRE) — OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its third quarter 2021 financial results after the close of the U.S. financial markets on Thursday, November 11, 2021. OpGen’s management team will host a live conference call and audio webcast at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide an update on business activities.

Conference Call Details  
U.S. Dial-in Number: 1-877-705-6003
International Dial-in Number: 1-201-493-6725
Webcast: http://public.viavid.com/index.php?id=146838 
Conference ID: 13723808
   
Replay Details  
U.S. Dial-in Number: 1-844-512-2921
International Dial-in Number: 1-412-317-6671
Replay PIN: 13723808

Following the conclusion of the conference call, a replay will be available through November 25, 2021. The live, listen-only webcast of the conference call may also be accessed by visiting the Investors section of the Company’s website at www.opgen.com. A replay of the webcast will be available following the conclusion of the call and will be archived on the Company’s website under Financials & Filings.

About OpGen, Inc.

OpGen, Inc. (Rockville, MD, USA) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease. Along with our subsidiaries, Curetis GmbH and Ares Genetics GmbH, we are developing and commercializing molecular microbiology solutions helping to guide clinicians with more rapid and actionable information about life threatening infections to improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs. OpGen’s product portfolio includes Unyvero, Acuitas AMR Gene Panel and Acuitas® Lighthouse, and the ARES Technology Platform including ARESdb, using NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction.

For more information, please visit www.opgen.com.

OpGen:
Oliver Schacht
President and CEO
InvestorRelations@opgen.com

OpGen Press Contact:
Matthew Bretzius
FischTank Marketing and PR
matt@fischtankpr.com

OpGen Investor Contact:
Max Colbert
Edison Group
mcolbert@edisongroup.com

Staff

Recent Posts

Patients Searching “Best Plastic Surgeon in America” Are Traveling for Clarity and Planning – Gruber Plastic Surgery Expands Out-of-Town Resources for 2026

Updated Fly-In Program outlines virtual consultations, travel timelines, recovery planning, and follow-up care for out-of-town…

25 minutes ago

Dr. Kunaal Jindal Sheds Light on His Signature Mommy Makeover, Which Includes his High Definition Tummy Tuck with Liposculpting and Breast Reshaping

A closer look at the artistry, technique, and philosophy behind Dr. Jindal's most sought-after transformation.…

26 minutes ago

Attune to Support Poppy Health’s $39M ARPA-H BREATHE Project in the U.S. Schools

VIENNA, Va., Dec. 19, 2025 /PRNewswire/ -- Attune announced today that the company will play…

3 hours ago

Feel30 Launches Austin-Based Telehealth Platform for Evidence-Proven TRT & Integrated At-Home Phlebotomy Services

AUSTIN, Texas, Dec. 19, 2025 /PRNewswire/ -- Feel30 , a telehealth platform specializing in testosterone…

3 hours ago

LISA LING JOINS TENDERCARE AS CHIEF CAREGIVER ADVOCATE & ADVISOR

– Will help address the difficult realities sandwich generation caregivers face with family caregiving –NEW…

3 hours ago

TENDERCARE LAUNCHING NATIONAL FAMILY CAREGIVING INFRASTRUCTURE, PARTNERING WITH THE AGING LIFE CARE ASSOCIATION® AND SUPPORTING THE CMS GUIDE MODEL PROGRAM

tendercare partnering with ALCA to raise national caregiving and eldercare industry standards;Selected as CMS GUIDE…

3 hours ago